Influence of multiple apolipoprotein A-I and B genetic variations on insulin resistance and metabolic syndrome in obstructive sleep apnea

Table 3 Association of risk of APOA-I, APOB level and their GRS with risks of insulin resistance and MetS

	Non-HOMA-IR vs HOMA-IR			Non-MetS vs MetS			Non-OSA vs moderate to severe OSA
	OR	95%CI	P	OR	95%CI	P	OR	95%CI	P
APOA-I GRS	0.923	0.880–0.968	< 0.001	0.886	0.845–0.929	< 0.001	0.983	0.920–1.049	0.600
APOA-I GRS*	0.917	0.869–0.967	0.001	0.870	0.827–0.916	< 0.001	0.994	0.924–1.070	0.874
APOB GRS	1.011	0.950–1.076	0.734	1.060	0.997–1.128	0.063	1.011	0.927–1.101	0.811
APOB GRS*	1.364	1.330–1.339	0.610	1.072	1.003–1.147	0.042	1.000	0.907–1.104	0.993
APOB/APOA-I	4.551	3.379–6.129	< 0.001	19.021	13.629–26.545	< 0.001	7.610	4.886–11.852	< 0.001
APOB/APOA-I *	2.285	1.657–3.150	< 0.001	14.488	10.093–20.797	< 0.001	3.237	1.993–5.258	< 0.001
APOA-I	0.573	0.414–0.792	< 0.001	0.131	0.093–0.184	< 0.001	1.307	0.828–2.063	0.250
APOA-I *	0.823	0.566–1.196	0.308	0.09	0.061–0.132	< 0.001	1.336	0.788–2.267	0.282
APOB	6.677	4.654–9.578	< 0.001	12.095	8.349–17.522	< 0.001	31.683	18.231–55.059	< 0.001
APOB*	3.168	2.139–4.691	< 0.001	6.098	4.109–9.051	< 0.001	8.582	4.653–45.830	< 0.001

HOMA-IR homeostasis model assessment of insulin resistance, GRS genetic risk score, Met S metabolic syndrome, APOA-I Apolipoprotein A-I, APOB Apolipoprotein B
^*Adjust for age, gender, BMI

ISSN: 1743-7075